on Microbix Biosystems Inc. (CVE:MBX)
Microbix to Present at IPVS 2026 with Innovative HPV Test Enhancement
Microbix Biosystems Inc., a Canadian life sciences company, will attend the 38th International Papillomavirus Society conference, IPVS 2026, in Athens, Greece from October 22-25, 2026. They will present a novel synthetic vaginal matrix aimed at enhancing the validation and quality management of HPV molecular assays used in cervical cancer screenings.
This development may impact laboratories significantly, offering a practical method for verifying HPV test performance, notably in self-collected specimens. Dr. Larry Vaughan and Pavel Zhelev emphasize the potential of this matrix to support wider adoption and validation of self-collection. The poster detailing this innovation will be available on Microbix's website post-conference.
Microbix's innovation supports the growing trend of self-collection in cervical cancer screening, providing reliable tools for laboratories globally.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Microbix Biosystems Inc. news